Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index; 21 of the 34 sources its claims cite were checked for support.
Abstract
BACKGROUND: Weight regain after weight loss is a major problem in the treatment of persons with obesity. METHODS: In a randomized, head-to-head, placebo-controlled trial, we enrolled adults with obesity (body-mass index [the weight in kilograms divided by the square of the height in meters], 32 to 43) who did not have diabetes. After an 8-week low-calorie diet, participants were randomly assigned for 1 year to one of four strategies: a moderate-to-vigorous-intensity exercise program plus placebo (exercise group); treatment with liraglutide (3.0 mg per day) plus usual activity (liraglutide group); exercise program plus liraglutide therapy (combination group); or placebo plus usual activity (placebo group). End points with prespecified hypotheses were the change in body weight (primary end point) and the change in body-fat percentage (secondary end point) from randomization to the end of the treatment period in the intention-to-treat population. Prespecified metabolic health-related end points and safety were also assessed. RESULTS: After the 8-week low-calorie diet, 195 participants had a mean decrease in body weight of 13.1 kg. At 1 year, all the active-treatment strategies led to greater weight loss than placebo: difference in the exercise group, -4.1 kg (95% confidence interval [CI], -7.8 to -0.4; P = 0.03); in the liraglutide group, -6.8 kg (95% CI, -10.4 to -3.1; P<0.001); and in the combination group, -9.5 kg (95% CI, -13.1 to -5.9; P<0.001). The combination strategy led to greater weight loss than exercise (difference, -5.4 kg; 95% CI, -9.0 to -1.7; P = 0.004) but not liraglutide (-2.7 kg; 95% CI, -6.3 to 0.8; P = 0.13). The combination strategy decreased body-fat percentage by 3.9 percentage points, which was approximately twice the decrease in the exercise group (-1.7 percentage points; 95% CI, -3.2 to -0.2; P = 0.02) and the liraglutide group (-1.9 percentage points; 95% CI, -3.3 to -0.5; P = 0.009). Only the combination strategy was associated with improvements in the glycated hemoglobin level, insulin sensitivity, and cardiorespiratory fitness. Increased heart rate and cholelithiasis were observed more often in the liraglutide group than in the combination group. CONCLUSIONS: A strategy combining exercise and liraglutide therapy improved healthy weight loss maintenance more than either treatment alone. (Funded by the Novo Nordisk Foundation and others; EudraCT number, 2015-005585-32; ClinicalTrials.gov number, NCT04122716.).
Overview
CoChat Summary
## TL;DR
In this randomized, placebo-controlled trial of adults with obesity who first lost weight on an 8-week low-calorie diet, exercise plus liraglutide maintained weight loss better than either treatment alone. The combination also produced broader metabolic benefits, including improved body-fat percentage, glycated hemoglobin, insulin sensitivity, cardiorespiratory fitness, and physical functioning.
## Key findings
- After the 8-week low-calorie diet, 195 participants had a mean body-weight decrease of 13.1 kg; these participants were randomized to 1 year of treatment.
- At 1 year, compared with placebo, mean weight change differed by -4.1 kg with exercise, -6.8 kg with liraglutide, and -9.5 kg with the combination.
- The combination reduced body-fat percentage by 3.9 percentage points, versus -1.7 percentage points compared with exercise and -1.9 percentage points compared with liraglutide; it was the only strategy associated with improvements in glycated hemoglobin, insulin sensitivity, and cardiorespiratory fitness.
- Mean total weight loss from baseline to end of trial was 15.7% in the combination group, 10.9% with exercise, 13.4% with liraglutide, and 6.7% with placebo.
## Methods
- Investigator-initiated, randomized, head-to-head, placebo-controlled trial at Hvidovre Hospital and the University of Copenhagen; participants were randomized in a 1:1:1:1 ratio after an 8-week 800-kcal/day low-calorie diet.
- Sample: adults 18 to 65 years with obesity (BMI 32 to 43) and no diabetes; 215 started the diet and 195 (those losing at least 5% of baseline weight) were randomized.
- Main analysis used an intention-to-treat repeated-measures linear regression model with time, group, sex, age group, and time-by-group interaction; prespecified supplementary analyses included per-protocol, adjustment for initial weight loss, and multiple imputation.
## Limitations
- The paper states results may not be generalizable to older persons (>65 years), persons with BMI >43, patients with type 2 diabetes, or persons with low adherence to moderate-to-vigorous exercise or limited ability to exercise.
- The authors note that some participants missed the week-52 assessment: 166 of 195 (85%) attended the primary endpoint visit.
- Evident from the text: the trial was conducted in Denmark at two sites and in participants who first achieved at least 5% weight loss on a low-calorie diet, so applicability to broader obesity populations and to people unable to lose weight initially is not directly tested.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
12 Valid · 1 Not valid · 3 Not checked · 76 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“and to increased appetite. 9-11”
What the sources say
- Not checked — no full text of the sourcecites [9] matched to “Successful weight loss maintenance includes long-term increased meal responses of GLP-1 and PYY3-36” (2016) source
- Not checked — no full text of the sourcecites [10] matched to “Long-term persistence of hormonal adaptations to weight loss” (2011) source
- Partly supportedcites [11] matched to “Treatment with a GLP-1 receptor agonist diminishes the decrease in free plasma leptin during maintenance of weight loss” (2015) sourceExperimental — accuracy not yet measured
The Introduction says that increased hunger and reduced satiety after weight loss are among the mechanisms favoring weight regain. It does not say that the regain is rapid, so the claim’s timing is unsupported. (LLM, conf=0.84)
plainstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Diet management programs, including the use of low-calorie mealreplacement products, can sustain low-calorie diet-induced weight loss with a small weight regain. 11,15-17”
What the sources say
- Supportedcites [11] matched to “Treatment with a GLP-1 receptor agonist diminishes the decrease in free plasma leptin during maintenance of weight loss” (2015) source
The Study design describes a dietician-supported maintenance program that allowed low-calorie meal replacements after an initial very low-calorie diet. The Discussion reports that both groups maintained an approximately 12-kg loss over one year, with weight regain of 0.4 kg in the GLP-1RA group and 2.3 kg in the control group. (LLM, conf=0.90)
- Supportedcites [15] matched to “Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial” (2018) source
The Procedures describe a low-energy formula diet followed by food reintroduction and a structured weight-loss maintenance programme. The Results report that participants who engaged lost 14.5 kg during diet replacement, then regained 1.0 kg during food reintroduction and 1.9 kg during weight-loss management. These findings support the claim for this programme in people with type 2 diabetes; page numbers were not supplied. (LLM, conf=0.91)
- Supportedcites [16] matched to “Doctor Referral of Overweight People to Low Energy total diet replacement Treatment (DROPLET): pragmatic randomised controlled trial” (2018) source
The Methods (Interventions; page not provided) describe an 810 kcal/day programme using formula food products, followed by a weight-maintenance phase. The Results (Table 2; page not provided) show that mean weight loss in the treatment group was 15.1 kg at six months and 10.7 kg at 12 months: some weight was regained, but substantial weight loss remained. The Discussion (Implications of this research; page not provided) likewise reports average regain after the programme ended while noting that participants maintained clinically important losses. (LLM, conf=0.87)
- Supportedcites [17] matched to “Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial” (2019) source
The Study design and participants section describes an initial low-calorie formula diet followed by structured weight-maintenance support, including meal replacement when weight was regained. The Results report that the intervention group remained an average of 7.6 kg below baseline at 24 months, despite an average 2.6 kg regain between months 12 and 24. Page numbers are not available in our copy. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Furthermore, lifestyle interventions that encourage increased physical activity concurrent with calorie restriction have been shown to sustain moderate weight loss. 18,19”
What the sources say
- Supportedcites [18] matched to “Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes” (2013) source
The Methods > Interventions passage describes a program combining reduced caloric intake with increased physical activity. The Results > Weight, Waist Circumference and Fitness and Discussion passages report that participants maintained a modest average weight loss of 6.0% at the end of the trial, supporting the claim for overweight or obese adults with type 2 diabetes. (LLM, conf=0.93)
- Not checked — no full text of the sourcecites [19] matched to “Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin” (2002) source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“However, the isolated benefits of exercise to prevent weight regain after weight loss is understudied. 20”
What the sources say
- Partly supportedcites [20] matched to “Is regular exercise an effective strategy for weight loss maintenance?” (2018) sourceExperimental — accuracy not yet measured
Section 2.1 (page unavailable) says randomized trials lack convincing evidence that exercise improves weight-loss maintenance, supporting uncertainty about its benefit. But it also discusses numerous trials and does not say that the isolated benefit of exercise, as distinct from other interventions, has been understudied. (LLM, conf=0.78)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“This is more than the total weight losses of approximately 10% that were obtained with 1-year diet-management programs after an initial low-calorie diet. 11,15,16,29”
What the sources say
- Supportedcites [11] matched to “Treatment with a GLP-1 receptor agonist diminishes the decrease in free plasma leptin during maintenance of weight loss” (2015) source
The Methods describe an initial 8-week very-low-calorie diet followed by a 52-week weight-maintenance program. The Results report an initial 12% weight loss (about 12 kg) and a 2.3 kg regain in the control group after 52 weeks, leaving approximately 10% total weight loss. The cited paper therefore supports the comparison with a roughly 10% loss after a year of diet management. (LLM, conf=0.90)
- Supportedcites [15] matched to “Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial” (2018) source
The Procedures section describes an initial low-energy total diet replacement phase followed by food reintroduction and ongoing weight-loss maintenance. Table S1 (Additional information) reports a 9.9% mean weight loss in the intervention group at 12 months, supporting the cited figure of approximately 10%. The 16% loss with the combination is the citing paper’s comparison, not a result attributed to DiRECT. (LLM, conf=0.92)
- Supportedcites [16] matched to “Doctor Referral of Overweight People to Low Energy total diet replacement Treatment (DROPLET): pragmatic randomised controlled trial” (2018) source
The Methods (Interventions; page unavailable) describe an initial 810 kcal/day total diet replacement followed by food reintroduction and weight-maintenance support. The Results (Primary outcome and baseline characteristics; page unavailable) report a mean loss of 10.7 kg at 12 months from a mean starting weight of 107.9 kg in that group—approximately 10%. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [29] matched to “Effect of intensive lifestyle intervention on bodyweight and glycaemia in early type 2 diabetes (DIADEM-I): an open-label, parallel-group, randomised controlled trial” (2020) source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
42 more claims · 2 with their cited sources checked
Create a free account to see all 92 claims and every source verdict.
- It may state two separate claims as one. 31
- Probably not a substantial claim. 21
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“the overall weight loss was also minimal, since the study was focused on the weight-maintenance period following active weight loss.”
From The Benefits of Exercise Training in Combination With Weight Loss Therapies (2025) · cites this paper as [45]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Only those in the combined therapy group showed sustained improvements in glycated hemoglobin levels, insulin sensitivity, and cardiorespiratory fitness at the 1-year follow-up in the trial.”
From The Benefits of Exercise Training in Combination With Weight Loss Therapies (2025) · cites this paper as [45]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Only those in the combined therapy group showed sustained improvements in glycated hemoglobin levels, insulin sensitivity, and cardiorespiratory fitness at the 1-year follow-up in the trial.”
From The Benefits of Exercise Training in Combination With Weight Loss Therapies (2025) · cites this paper as [45]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“The combination group had a substantial weight reduction of −12.1 kg compared with placebo26, which might in itself increase appetite6.”
From Exploratory analysis of eating-and physical activity-related outcomes from a randomized controlled trial for weight loss maintenance with exercise and liraglutide single or combination treatment (2022) · cites this paper as [26]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Weight loss was maintained in the exercise group with a treatment effect of −5.3 kg compared with placebo26.”
From Exploratory analysis of eating-and physical activity-related outcomes from a randomized controlled trial for weight loss maintenance with exercise and liraglutide single or combination treatment (2022) · cites this paper as [26]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measured
41 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011 · cited 2×
“Diarrhea 38 (19) 4 (8) 7 (15) 13 (27) 14 (29)”
World Health Organization 2020 guidelines on physical activity and sedentary behaviour
Bull, F. C., Al-Ansari, S. S., Biddle, S., Borodulin, K., Buman, M. P., Cardon, G., Carty, C., Chaput, J.-P., Chastin, S., Chou, R., et al. (2020) · British Journal of Sports Medicine · doi:10.1136/bjsports-2020-102955 · Cited by 11,657 · cited 4×
“Abdominal pain 46 (24) 3 (6) 13 (27) 18 (37) 12 (24)”
InfluentialMatsuda, M., & DeFronzo, R. A. (1999) · Diabetes Care · doi:10.2337/diacare.22.9.1462 · Cited by 5,621
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes
The Look AHEAD Research Group (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1212914 · Cited by 2,908
Jensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., Hu, F. B., Hubbard, V. S., Jakicic, J. M., Kushner, R. F., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437739.71477.ee · Cited by 2,735 · cited 4×
“Adverse event that led to the discontinuation of liraglutide or placebo 5 (3) 0 3 (6) 1 (2) 1 (2)”
BackgroundInfluentialA Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Ross, R., Blair, S. N., Arena, R., Church, T. S., Després, J.-P., Franklin, B. A., Haskell, W. L., Kaminsky, L. A., Levine, B. D., Lavie, C. J., et al. (2016) · Circulation · doi:10.1161/cir.0000000000000461 · Cited by 2,486
Lean, M. E., Leslie, W. S., Barnes, A. C., Brosnahan, N., Thom, G., McCombie, L., Peters, C., Zhyzhneuskaya, S., Al-Mrabeh, A., Hollingsworth, K. G., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)33102-1 · Cited by 2,095 · cited 2×
“Diarrhea 38 (19) 4 (8) 7 (15) 13 (27) 14 (29)”
Changes in Energy Expenditure Resulting from Altered Body Weight
Leibel, R. L., Rosenbaum, M., & Hirsch, J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199503093321001 · Cited by 2,012 · cited 7×
“Serious adverse event† 16 (8) 2 (4) 4 (8) 6 (12) 4 (8)”
Influential
Cited by
Items 101–200 of 526
Singh, A., Aggarwal, M., Garg, R., Stevens, T., & Chahal, P. (2022) · Annals of Medicine · doi:10.1080/07853890.2022.2090601 · Cited by 33
“Another challenge is the associated weight loss with GLP-1 analogues which can theoretically worsen malnutrition in PPDM patients [82,83].”
BackgroundLin, Q., Xue, Y., Zou, H., Ruan, Z., Ung, C. O. L., & Hu, H. (2022) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2022.2130760 · Cited by 38
“One patient with two cases of pancreatitis (acute pancreatitis and pancreatitis, both were graded as serious) was reported with placebo in SCALE Insulin [24], and one patient with two cases of acute pancreatitis was reported with liraglutide in S-LiTE [26].”
BackgroundInfluentialJalleh, R. J., Talley, N. J., Horowitz, M., & Nauck, M. A. (2026) · Journal of Clinical Investigation · doi:10.1172/jci194740 · Cited by 40
“Use of protein supplements has not yet been adequately evaluated in individuals on GLP-1RAs, but there is evidence that an exercise program may increase the proportion of fat mass loss, as opposed to loss of fat-free mass (124).”
Hu, S., Su, X., & Fan, G. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01195-7 · Cited by 28
“Exercise not only increases the number and sensitivity of insulin receptors on cell membranes but also improves insulin resistance, which can control blood glucose, indirectly [38–40].”
BackgroundLi, H., Yu, G., Huang, Q., Yang, B., Nie, J., Liu, Y., & Tu, X. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116150 · Cited by 38
Treating sarcopenic obesity in the era of incretin therapies: perspectives and challenges
Chen, A. S., & Batsis, J. A. (2025) · Diabetes · doi:10.2337/dbi25-0004 · Cited by 32
Tuccinardi, D., Masi, D., Watanabe, M., Zanghi Buffi, V., De Domenico, F., Berti, S., Cipriani, V., Manco, M., Manfrini, S., & Pagotto, U. (2025) · Journal of Endocrinological Investigation · doi:10.1007/s40618-025-02700-7 · Cited by 29
“Liraglutide combined with resistance training and high-protein intake has demonstrated preservation of lean mass and strength, making it a suitable option in this setting [201].”
London, A., Richter, M. M., Sjøberg, K. A., Albrechtsen, N. J. W., Považan, M., Drici, L., Schaufuss, A., Madsen, L., Øyen, J., Madsbad, S., et al. (2024) · American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2024.06.006 · Cited by 31
Self-citationYin, Y., Zhang, M., Cao, Q., Lin, L., Lu, J., Bi, Y., & Chen, Y. (2025) · Journal of Diabetes · doi:10.1111/1753-0407.70082 · Cited by 35
Torbahn, G., Lischka, J., Brown, T. J., Ells, L. J., Kelly, A. S., Wabitsch, M., & Weghuber, D. (2024) · Clinical Endocrinology · doi:10.1111/cen.15133 · Cited by 33
Zhou, L., Shen, H., Li, X., & Wang, H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.951406 · Cited by 30
Cui, B., Wang, G., Li, P., Li, W., Song, Z. J., Sun, X., Zhu, L., & Zhu, S. (2023) · International Journal of Surgery · doi:10.1097/js9.0000000000000066 · Cited by 30
“Despite pharmacological treatment targeting metabolic control seems to be a promising strategy for weight management, its long-term ef fi cacy needs to be further con fi rmed [9,10] .”
Jakicic, J. M., Apovian, C. M., Barr‐Anderson, D. J., Courcoulas, A. P., Donnelly, J. E., Ekkekakis, P., Hopkins, M., Lambert, M., Napolitano, M. A., & Volpe, S. L. (2024) · Translational Journal of the American College of Sports Medicine · doi:10.1249/tjx.0000000000000266 · Cited by 34
Physiology of Weight Regain after Weight Loss: Latest Insights
van Baak, M. A., & Mariman, E. C. M. (2025) · Current Obesity Reports · doi:10.1007/s13679-025-00619-x · Cited by 40
“A study by Lundgren and coworkers (2021) [40] showed that exercise training after diet-induced weight loss resulted in a more favourable change in body composition (more increase in lean mass) associated with weight regain during follow-up than liraglutide treatment.”
Sievenpiper, J. L., Ard, J. D., Blüher, M., Chen, W., Dixon, J. B., Fitch, A., Gigliotti, L., Khunti, K., Lecube, A., Lean, M., et al. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100228 · Cited by 58
“An individualized physical activity program based on ≥ 150 min of moderate to vigorous intensity aerobic activity and 2 – 3 sessions of resistance training per week, if possible, is recommended to maintain muscle function and support active weight loss [84,160].”
Jobanputra, R., Sargeant, J. A., Almaqhawi, A., Ahmad, E., Arsenyadis, F., Webb, D. R., Herring, L. Y., Khunti, K., Davies, M. J., & Yates, T. (2023) · Obesity Reviews · doi:10.1111/obr.13553 · Cited by 22
“One study reported objectively measured physical function(4) and one cardiorespiratory fitness.(32) The characteristics of the included studies are provided in Table 1.”
BackgroundMethodResultInfluentialType 2 Diabetes Remission with Significant Weight Loss: Definition and Evidence-Based Interventions
Ko, J. H., & Kim, T. N. (2022) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes22001 · Cited by 31
Intranasal Oxytocin for Obesity
Plessow, F., Kerem, L., Wronski, M., Asanza, E., O’Donoghue, M. L., Stanford, F. C., Eddy, K. T., Holmes, T. M., Misra, M., Thomas, J. J., et al. (2024) · NEJM Evidence · doi:10.1056/evidoa2300349 · Cited by 29
Kim, D. D., Hwang, J. H., & Fendrick, A. M. (2024) · Health Affairs Scholar · doi:10.1093/haschl/qxae055 · Cited by 21
“27,28 In the example scenario where the alternative maintenance program is half the price of continuous full-dose IMs and 30% as effective (ie, patients regain 70% of their weight and lose 70% of the long-term clinical benefit), a net lifetime savings of $35 100 results.”
BackgroundIncretin hormone agonists: Current and emerging pharmacotherapy for obesity management
Alhomoud, I. S., Talasaz, A. H., Chandrasekaran, P., Brown, R., Mehta, A., & Dixon, D. L. (2024) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.4607 · Cited by 28
Balancing weight and muscle loss in GLP1 receptor agonist therapy
Sanchis‐Gomar, F., Neeland, I. J., & Lavie, C. J. (2025) · Nature Reviews Endocrinology · doi:10.1038/s41574-025-01160-6 · Cited by 25
“Notably, combining exercise with liraglutide has demonstrated enhanced adipose tissue loss compared to that observed with either single treatment (exercise or liraglutide alone) without compromising lean mass 9 .”
Lubberding, A. F., Juhl, C. R., Skovhøj, E. Z., Kanters, J. K., Mandrup-Poulsen, T. R., & Torekov, S. S. (2022) · Acta Physiologica · doi:10.1111/apha.13781 · Cited by 22
Self-citationHow can physical activity facilitate a sustainable future? Reducing obesity and chronic disease
Stensel, D. J. (2023) · Proceedings of The Nutrition Society · doi:10.1017/s0029665123002203 · Cited by 26
Jensen, S. B. K., Juhl, C. R., Janus, C., Lundgren, J. R., Martinussen, C., Wiingaard, C., Knudsen, C., Frikke‐Schmidt, R., Stallknecht, B. M., Holst, J. J., et al. (2023) · Obesity · doi:10.1002/oby.23715 · Cited by 32
“DATA AVAILABILITY STATEMENT The study protocol and statistical analysis plan have been published [21, 22].”
BackgroundMethodResultInfluentialSelf-citationDebating Weight Loss vs. Weight Neutral Strategies for Improvements of Health
Heitmann, B. L., Køster‐Rasmussen, R., Meyer, L. B., Larsen, S. C., Þorsteinsdóttir, F., Sandholdt, C. T., Bojsen-Møller, K. N., Overbeck, G., Waldorff, F. B., Kousgaard, M. B., et al. (2024) · Current Obesity Reports · doi:10.1007/s13679-024-00587-8 · Cited by 23
“…agonist liraglutide compared to a weight regain of 6.1 kg in participants randomised to no intervention (placebo-injections without exercise) [27], found that participants randomised to combined exercise and liraglutide lost an additional 3.4 kg in the period following the initial…”
BackgroundInfluentialSelf-citationChen, J., Kaur, H., Jaques, J., Rock, Z., Dean, C. M., Lord, R. V., & Preda, V. A. (2022) · Clinical Obesity · doi:10.1111/cob.12520 · Cited by 23
Pharmacological profile of once-weekly injectable semaglutide for chronic weight management
Lau, D. C. W., Batterham, R. L., & le Roux, C. W. (2022) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2022.2070473 · Cited by 27
“0 mg per day) improved healthy weight loss maintenance than either treatment alone [54].”
BackgroundPark, S., Oh, S., & Kim, E. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102682 · Cited by 20
“This might be due to the fact that liraglutide does not completely revert the obese phenotype to a nonobese state, but makes the phenotype milder (19, 60, 61).”
BackgroundInsufficient sleep predicts poor weight loss maintenance after 1 year
Bogh, A. F., Jensen, S. B. K., Juhl, C. R., Janus, C., Sandsdal, R. M., Lundgren, J. R., Noer, M. H., Vu, N. Q., Fiorenza, M., Stallknecht, B. M., et al. (2022) · SLEEP · doi:10.1093/sleep/zsac295 · Cited by 26
“The present study is based on data from the S-LiTE randomized, controlled trial [28, 29].”
MethodSelf-citationCurrent and emerging medications for the management of obesity in adults
Walmsley, R., & Sumithran, P. (2023) · The Medical Journal of Australia · doi:10.5694/mja2.51871 · Cited by 25
Why are we still in need for novel anti-obesity medications?
Novikoff, A., Grandl, G., Liu, X., & Müller, T. D. (2024) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2024.101098 · Cited by 22
“33 Nonetheless, as previously mentioned, combining GLP-1 therapy with myostatin or activin type II receptor inhibition could promote favorable body compositional changes, leading to a predicted increase in resting energy expenditure, and thus potentially an easier path toward weight and fat mass…”
Exploring the wider benefits of semaglutide treatment in obesity: insight from the STEP program.
O’Neil, P. M., & Rubino, D. M. (2022) · Postgraduate Medicine · doi:10.1080/00325481.2022.2150006 · Cited by 19
“0 mg, oral semaglutide, and liraglutide, which showed that weight loss with these agents was predominantly due to loss of fat mass rather than lean body mass [60,62,63].”
Physical activity, inactivity and sleep during the Diabetes Remission Clinical Trial (DiRECT)
Cassidy, S., Trenell, M., Stefanetti, R. J., Charman, S. J., Barnes, A. C., Brosnahan, N., McCombie, L., Thom, G., Peters, C., Zhyzhneuskaya, S., et al. (2023) · Diabetic Medicine · doi:10.1111/dme.15010 · Cited by 19
Obesity and Exercise: New Insights and Perspectives
James, N. M., & Stanford, K. I. (2025) · Endocrine Reviews · doi:10.1210/endrev/bnaf017 · Cited by 20
The role of incretin receptor agonists in the treatment of obesity
Forst, T. M., Block, C. E. M. D., Prato, S. D., Armani, S., Frías, J. P., Lautenbach, A., Ludvik, B. H., Marinez, M., Mathieu, C., Müller, T. D., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15796 · Cited by 22
“52,53 Liraglutide can also be effective for The main biological actions of incretins and other hormones in obesity 26,28,35,39 – 44 ,”
Anyiam, O., Rashid, R. S. A., Bhatti, A. I., Khan-Madni, S., Ogunyemi, O., Ardavani, A., & IDRIS, I. R. (2024) · Nutrients · doi:10.3390/nu16193328 · Cited by 24
CVOT summit report 2024: new cardiovascular, kidney, and metabolic outcomes
Schnell, O., Almandoz, J. P., Anderson, L., Barnard-Kelly, K. D., Battelino, T., Blüher, M., Busetto, L., Catrinou, D., Ceriello, A., Cos, X., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02700-0 · Cited by 24
“[129].”
The Role of the Gut Microbiome in Pediatric Obesity and Bariatric Surgery
Akagbosu, C., Nadler, E. P., Levy, S., & Hourigan, S. K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232315421 · Cited by 26
“Liraglutide is a glucagon-like peptide 1 (GLP-1) agonist whose approval was extended to adolescents aged 12 to 17 in 2020 [14].”
BackgroundPharmacotherapy of Weight‐loss and Obesity with a Focus on GLP 1‐Receptor Agonists
Myerson, M. L., & Paparodis, R. D. (2024) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.2487 · Cited by 20
Schmidt, P. H. S., Pasqualotto, E., dos Santos, H. V., de Souza, L. S. N., dos Santos, B. E., Chavez, M. P., Ferreira, R. O. M., Hohl, A., Ronsoni, M. F., & van de Sande-Lee, S. (2025) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2025.01.009 · Cited by 18
Choudhury, A., Boxtel, M. V., & Hanley, J. (2024) · Seminars in Arthroplasty JSES · doi:10.1053/j.sart.2024.10.001 · Cited by 21
Síndrome metabólico: revisión de la literatura
Fragozo-Ramos, M. C. (2022) · Medicina y Laboratorio · doi:10.36384/01232576.559 · Cited by 64
Physical Activity, Obesity and Weight Loss Maintenance
Brandt, C., & Pedersen, B. K. (2022) · Handbook of experimental pharmacology · doi:10.1007/164_2021_575 · Cited by 23
He, F., Chen, W., Xu, W., Liu, D., Xiao, Z., Tang, Y., Lin, Z., Liao, Y., Bin, J., Chen, G., et al. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14908 · Cited by 21
“Previous studies have shown that lifestyle interventions plus liraglutide were more effective than liraglutide alone for weight loss.(30) However, there is no such evidence about visceral fat.”
BackgroundEpicardial Fat in Heart Failure with Preserved Ejection Fraction: Bad Actor or Just Lying Around?
Oduah, M.-T. A., Sundaram, V., & Reddy, Y. N. V. (2023) · Cardiac failure review · doi:10.15420/cfr.2022.25 · Cited by 20
Stefanakis, K., Kokkinos, A. D., Argyrakopoulou, G., Konstantinidou, S. M., Simati, S., Kouvari, M., Kumar, A., Kalra, B., Kumar, M., Bontozoglou, N., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15141 · Cited by 20
“N/B 126 (15) 116 (19)** 110 (18)*** Trt .”
Pharmacotherapy as an Augmentation to Bariatric Surgery for Obesity
Horváth, L., Mráz, M., Jude, E. B., & Haluzík, M. (2024) · Drugs · doi:10.1007/s40265-024-02029-0 · Cited by 22
Despain, D., & Hoffman, B. L. (2024) · Obesity Pillars · doi:10.1016/j.obpill.2024.100143 · Cited by 19
“This is consistent with previous studies demonstrating that lifestyle changes, such as continuing an exercise program, is effective in assisting with weight loss maintenance [17,18].”
ResultRecent progress in the pharmacotherapy for obesity
Lu, J., Liu, P., Cai, M., Lv, T., Zhang, M., Yin, K., Cheng, J., & Zhang, G. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177850 · Cited by 17
The Impact and Safety of GLP‐1 Agents and Breast Cancer
Parsons, K., Montalvo, M., Fischbach, N. A., Taylor, M. A., Alfaro, S., & Lustberg, M. B. (2025) · Cancer Medicine · doi:10.1002/cam4.70932 · Cited by 24
Valladales‐Restrepo, L. F., Sánchez-Ramírez, N., Usma-Valencia, A. F., Gaviria‐Mendoza, A., Machado‐Duque, M. E., & Machado‐Alba, J. E. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2178900 · Cited by 21
“widely evidenced in the literature [20,26,27,36].”
The combined effect of metformin and mirabegron on diet‐induced obesity
Zhao, X., Liu, Y., Zhang, X., Zhao, B., Burley, G., Yang, Z., Luo, Y., Li, A., Zhang, R., Liu, Z., et al. (2023) · MedComm · doi:10.1002/mco2.207 · Cited by 18
de Moraes, F. C. A., Morbach, V., Sano, V. K. T., Fernandes, L. R., Kreuz, M., & Kelly, F. A. (2024) · Obesity Surgery · doi:10.1007/s11695-024-07384-1 · Cited by 21
“Although the studies that have evaluated liraglutide examine weight loss and treatment safety, there is still little information on its cardiometabolic benefits and impact on the recurrence of obesity-related comorbidities [29, 30].”
Eisa, N., & Barood, O. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70666 · Cited by 48
Kubota, M., Yamamoto, K., & Yoshiyama, S. (2023) · Cureus · doi:10.7759/cureus.46490 · Cited by 16
The Benefit of Healthy Lifestyle in the Era of New Medications to Treat Obesity
Grave, R. D. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s447582 · Cited by 19
“9 Weight loss does not automatically result in increased muscle strength; to this end, specific resistance exercises should be included in weight-loss treatment.”
BackgroundXu, Y., Echouffo Tcheugui, J. B., Coresh, J., Grams, M. E., Selvin, E., Fang, M., & Shin, J. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.16300 · Cited by 15
Treat to target in weight management with semaglutide: Real‐world evidence from an eHealth clinic
Seier, S., Stamp‐Larsen, K., Jensen, S. B. K., Torekov, S. S., & Gudbergsen, H. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.70096 · Cited by 15
“25 Obesity medication is predominantly prescribed by general practitioners, 24 which may make it difficult to provide the concomitant high-quality, non-pharmacological lifestyle component important for optimal health outcomes.”
Self-citationTinsley, G. M., & Nadolsky, S. (2025) · SAGE Open Medical Case Reports · doi:10.1177/2050313x251388724 · Cited by 15
“In that regard, Lundgren et al. 20 demonstrated that the addition of an exercise program to lira-glutide treatment preserved FFM and potentiated FM loss following an initial low-calorie diet period, eliciting weight loss.”
Katzman, J. L., Haider, M. A., Cardillo, C., Rozell, J. C., Schwarzkopf, R. M., & Lajam, C. M. (2025) · The Journal of Arthroplasty · doi:10.1016/j.arth.2025.02.042 · Cited by 19
Mesinovic, J., Hurst, C., Leung, G. K. W., Ryan, J. R., Daly, R. M., & Scott, D. (2025) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-025-09968-3 · Cited by 26
“…effects of AT and RT on musculoskeletal outcomes during ER have been reported elsewhere [57, 182–184] and in the context of other weight loss approaches such as BS [125, 185, 186] and incretin-mimetics [187, 188], although RCTs prescribing RT in conjunction with new-generation drugs are lacking.”
Lifestyle Intervention for Sustained Remission of Metabolic Syndrome: A Randomized Clinical Trial
Powell, L. H., Berkley‐Patton, J., Drees, B. M., Karavolos, K., Lohse, B., Masters, K. S., Nicklas, J. M., Rothschild, S. K., Yeh, C., Zimmermann, L. J., et al. (2025) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2025.5900 · Cited by 26
Mount, S., Canfora, E. E., Jocken, J. W. E., Umanets, A., Hul, G. B. J., Coenjaerds, M. M. J., Laquidain, P. A., Adriaens, M. E., Holst, J. J., Jardon, K. M. C., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04394-7 · Cited by 35
“A total of 108 participants were estimated to be required for this study, using data from two previous WL/WM studies 52 and the EU Horizon 2020 SWEET study.”
Self-citationDONALD, E. M., Driggin, E., Choe, J. Y., Batra, J., Vargas, F., Lindekens, J., Fried, J., Raikhelkar, J., Bae, D. J., Oh, K. T., et al. (2024) · Clinical Transplantation · doi:10.1111/ctr.15401 · Cited by 15
Incretin Receptor Agonism, Fat-free Mass, and Cardiorespiratory Fitness: A Narrative Review
Liu, Z., Weeldreyer, N. R., & Angadi, S. S. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf335 · Cited by 21
Fiorenza, M., Checa, A., Sandsdal, R. M., Jensen, S. B. K., Juhl, C. R., Noer, M. H., Bogh, N. P., Lundgren, J. R., Janus, C., Stallknecht, B. M., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101629 · Cited by 14
Self-citationVo, N., Zhang, Q., & Sung, H. (2024) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.3389/jpps.2024.13062 · Cited by 18
Interactions of physical activity, muscular fitness, adiposity, and genetic risk for NAFLD
Schnurr, T. M., Katz, S. F., Justesen, J. M., O’Sullivan, J. W., Saliba‐Gustafsson, P., Assimes, T. L., Carcamo‐Orive, I., Ahmed, A., Ashley, E. A., Hansen, T. F., et al. (2022) · Hepatology Communications · doi:10.1002/hep4.1932 · Cited by 15
“A recent randomized weight loss trial investigated the effect of exercise, liraglutide, and both treatments combined for healthy weight- loss maintenance and found that the combined strategy of pharmacotherapy and exercise reduced body weight and body- fat percentage approximately twice as much as the singletreatment…”
BackgroundNoronha, J. C., Thom, G., & Lean, M. E. J. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.888557 · Cited by 15
Frampton, J., Serrano-Contreras, J. I., García‐Pérez, I., Franco‐Becker, G., Penhaligan, J., Tan, A. S. Y., de Oliveira, A. C. C., Milner, A. J., Murphy, K. G., Frost, G. S., et al. (2023) · The Journal of Physiology · doi:10.1113/jp284294 · Cited by 15
“Recent studies investigating GLP-1 receptor agonists and exercise training have reported greater weight loss when using both interventions concurrently vs. either intervention alone (Lundgren et al., 2021).”
Petersen, J., Merrild, C., Lund, J., Holm, S., & Clemmensen, C. (2024) · Molecular Metabolism · doi:10.1016/j.molmet.2024.102027 · Cited by 13
“This observation is supported by earlier fi ndings with the GLP-1R agonist liraglutide demonstrating that an 8-week lead-in period with low-calorie dieting improved markers of cardiometabolic health beyond liraglutide treatment alone in adults with obesity [18,37].”
Barana, L., De Fano, M., Cavallo, M., Manco, M., Prete, D., Fanelli, C. G., Porcellati, F., & Pippi, R. (2025) · Nutrients · doi:10.3390/nu18010131 · Cited by 13
“Some authors have shown that AOMs are more effective in WL than the lifestyle approach alone [62,125]; for example, Wadden et al. reported that WL induced by lifestyle modification is approximately 5–10% [62].”
Effect of Incretin-Based and Nonpharmacologic Weight Loss on Body Composition: A Systematic Review
Batsis, J. A., Gavras, A., Gross, D. C., Cheever, C. R., da Silva, B. R., Filho, L. F. M., Jones, E. P., Batchek, D. J., Khandpekar, S. G., Patel, R., et al. (2026) · Annals of Internal Medicine · doi:10.7326/annals-25-00478 · Cited by 34
Martikainen, J. A., Lehtimäki, A.-V., Jalkanen, K., Lavikainen, P., Paajanen, T. I., Marjonen, H., Kristiansson, K., Lindström, J., & Perola, M. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.880799 · Cited by 12
“Therefore, for simplicity, it was assumed that 30% of persons receiving a lifestyle intervention would also be applicable to receive a medical intervention which was estimated to result in a weight loss of over 5% (Lundgren et al., 2021).”
BackgroundHealth Disparity Clusters of Off Label Prescriptions for Glucagon-Like Peptide 1 Receptor Agonists
Spinelli, K. J., Oakes, A. H., Chiu, S., Imboden, M. T., Miller, A. B., Jain, S., & Gluckman, T. J. (2025) · American Journal of Medicine Open · doi:10.1016/j.ajmo.2025.100100 · Cited by 16
“36 , 37 This approach to care should also help to strengthen the clinician-patient relationship and lessen inequities related to access and utilization of services that stem from mistrust in the medical system within Black, Hispanic, American Indian, and other racial and ethnic communities.”
Biology and Clinical Use of Glucagon-Like Peptide-1 Receptor Agonists in Vascular Protection
Yau, K., Odutayo, A., Dash, S., & Cherney, D. Z. I. (2023) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2023.07.007 · Cited by 21
Takrori, E., Peshin, S., & Singal, S. (2025) · Medicina · doi:10.3390/medicina61111987 · Cited by 13
“Trials in which participants were pre-informed about likely GI symptoms, such as those by Rodgers et al. and Lundgren et al., reported higher adherence and lower dropout rates [9,10].”
Swift, D. L., Ross, L. M., Laddu, D. R., Conroy, M. B., German, C. A., Evangelista, L. S., Marvel, F. A., Jerome, G. J., on behalf the American Heart Association Council on Lifestyle and Cardiometabolic Health, Council on Cardiovascular and Stroke Nursing, et al. (2026) · Circulation · doi:10.1161/cir.0000000000001441 · Cited by 13
Exercise for Clients Taking an Anti-Obesity Medication
Rogers, R. J. (2024) · ACSM'S Health & Fitness Journal · doi:10.1249/fit.0000000000000959 · Cited by 12
Ben‐Porat, T., Dagan, S. S., Côté, M., Miner, C. J., & Buch, A. (2025) · Advances in Nutrition · doi:10.1016/j.advnut.2025.100522 · Cited by 18
“…there is strong evidence that structured lifestyle modification programs improve health in patients living with obesity, but there is a lack of information on the impact of such interventions in the context of incretin-based OMMs and the unique challenges they pose for patients [9,10,16,17,58].”
Playdon, M. C., Hardikar, S. S., Karra, P., Hoobler, R., Ibele, A. R., Cook, K. L., Kumar, A., Ippolito, J. E., & Brown, J. C. (2023) · JNCI Monographs · doi:10.1093/jncimonographs/lgad003 · Cited by 14
“For example, MBS has been combined with obesity pharmacotherapy (109,110), and obesity pharmacotherapy has been combined with intensive lifestyle modification (111) to generate synergy to reduce body weight and excess adiposity.”
BackgroundLandgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H., Müller-Wieland, D., Nauck, M. A., Wiesner, T., & Siegel, E. (2022) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1624-3449 · Cited by 12
Zhao, G., Zhang, Q., Wu, F., Yin, S., Xie, Y., & Liu, H. (2022) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2022.2117152 · Cited by 16
“Owing to the need for children to go to school and patient compliance, better programme design is necessary to control the amount of exercise in child treatment programmes, for example liraglutide combined with exercise [42], or a new drug of Glucagon-like peptide-1 receptor agonist, Semaglutide that has been used in…”
Mutational Landscape of the Proglucagon-Derived Peptides
Lindquist, P., Madsen, J. S., Bräuner‐Osborne, H., ROSENKILDE, M. M., & Hauser, A. S. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.698511 · Cited by 14
“dulaglutide, liraglutide and semaglutide), and the novel glucagon analog (dasiglucagon) essential for controlling metabolism and blood glucose levels in the treatment of type-2diabetic patients (3, 4, 6, 97).”
BackgroundBabazadeh, D., Wyatt, S., & Steinberg, F. M. (2025) · Advances in Nutrition · doi:10.1016/j.advnut.2025.100491 · Cited by 16
“Seventeen studies reported outcomes related to food cravings or eating behaviors such as hunger, food preferences, and cravings (Table 2) [9,41 – 43, 57 ,70,77,81, 82,”
Jagtap, U. A., & Paul, A. T. (2025) · RSC Medicinal Chemistry · doi:10.1039/d5md00373c · Cited by 12
Spanggaard, M., Bøgelund, M., Dirksen, C., Jørgensen, N. B., Madsbad, S., Panton, U. H., Pedersen, M. H., Reitzel, S. B., & Johansen, P. (2022) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2022.2053676 · Cited by 14
“Few effective treatment options are available for people with obesity [29].”
BackgroundSelf-citationWallace, R., Hamblin, P. S., Tully, E. K., Tran, J., Nelson, C., & Levidiotis, V. (2024) · Nephrology · doi:10.1111/nep.14277 · Cited by 12
Rosa, C. D., Larson, L. R., Collado, S., Geiger, S. J., Profice, C. C., & Menuchi, M. R. T. P. (2024) · Journal of Environmental Psychology · doi:10.1016/j.jenvp.2024.102438 · Cited by 15
He, L., Li, J., Cheng, X., Luo, L., & Huang, Y. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1509561 · Cited by 16
Domazet, S. L., Tarp, J., Thomsen, R. W., Højlund, K., Stidsen, J. V., Brønd, J. C., Grøntved, A., & Nielsen, J. S. (2023) · Frontiers in Sports and Active Living · doi:10.3389/fspor.2022.1089579 · Cited by 11
“Physical activity has further been found to improve healthy weight loss maintenance in non-diabetic obese adults more than drug therapy or exercise alone (40).”
BackgroundBrethvad, A. O., Zakariassen, H. L., Holt, J., Lundgren, J. R., Jakobsen, A., Hartmann, B., Lehmann, E. W., Kissow, H., Holst, J. J., Madsbad, S., et al. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155534 · Cited by 11
“Furthermore, we have recently shown that combination of a GLP-1 receptor agonist and exercise further enhanced diet-induced weight loss during a 1 year follow up period [7].”
BackgroundInfluentialSelf-citationRELA governs a network of islet-specific metabolic genes necessary for beta cell function
Zammit, N. W., Wong, Y. Y., Walters, S. N., Warren, J., Barry, S. C., & Grey, S. T. (2023) · Diabetologia · doi:10.1007/s00125-023-05931-6 · Cited by 11
“These insights place RELA among a suite of factors that influence healthy metabolism, including external factors such as exercise [42], antibiotics and glucose-lowering drugs [43], as well as molecular components of glucose sensing and insulin release such as voltage-gated K+ channels [44].”
Semaglutide for weight loss and cardiometabolic risk reduction in overweight/obesity
Mares, A. C., Chatterjee, S., & Mukherjee, D. (2022) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000955 · Cited by 11
“Liraglutide (Saxenda) [16] 2014 Liraglutide is a long-acting analog of human GLP-1 (an incretin hormone) which increases glucosedependent insulin secretion, decreases inappropriate glucagon secretion, increases B-cell growth/replication, slows gastric emptying, and decreases food intake Initial: 0.”
BackgroundChin, E. C., Leung, C. K., Yu, D. J., Yu, A. P., Bernal, J. D. K., Lai, C. W. K., Chan, D. K. C., Ngai, H. H. Y., Yung, P. S., Lee, C., et al. (2022) · Journal of Exercise Science & Fitness · doi:10.1016/j.jesf.2022.03.003 · Cited by 14
Body weight regulation models in humans: insights for testing their validity
Fernández‐Verdejo, R., Ravussin, É., & Galgani, J. E. (2025) · Nature Reviews Endocrinology · doi:10.1038/s41574-025-01149-1 · Cited by 11
“Notably, the obesogenic environment might also blunt weight loss efforts and promote weight regain following interventions 87,108,194 .”
Targeting Sarcopenia in CKD: The Emerging Role of GLP-1 Receptor Agonists
Llinares-Arvelo, V., Martínez‐Alberto, C. E., González-Luis, A., Macía-Heras, M., Siverio-Morales, O., Navarro‐González, J. F., & Donate‐Correa, J. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26168096 · Cited by 15
“Moderate exercise has been shown to support healthier weight loss and lean mass preservation when combined with GLP-1RAs [151,152], reinforcing the idea that combined interventions may be necessary to optimize outcomes.”
Aimelet, V., & Holst, J. J. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70229 · Cited by 15
“2 Although resistance training and adequate protein intake can effectively counteract lean body mass loss, 17,42 adherence to such guidelines is often low, especially among older adults 43 and individuals with severe obesity, 44 partly because these populations frequently belong to…”
Self-citationThe evolving landscape of obesity pharmacotherapy
Petersen, J., Finan, B., Johansen, V. B. I., Müller, T. D., & Clemmensen, C. (2026) · Nature Reviews Drug Discovery · doi:10.1038/s41573-026-01427-1 · Cited by 19
“Preceding tirzepatide therapy with intensive lifestyle intervention enhanced maximal attainable weight-loss outcomes 128 , although this strategy appears to be broadly effective for incretin-based therapies 129,130 .”
Moreira, R. O., Valério, C. M., Hohl, A., Moulin, C., Moura, F., Trujilho, F. R., Gerchman, F., Corrêa, L. L., Mancini, M. C., de Melo, M. E., et al. (2024) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-4292-2024-0422 · Cited by 29
“(58).”
Influential
Metadata
- Authors
- Lundgren, J. R., Janus, C., Jensen, S. B. K., Juhl, C. R., Olsen, L. M., Christensen, R. M., Svane, M. S., Bandholm, T., Bojsen-Møller, K. N., Blond, M. B., Jensen, J.-E. B., Stallknecht, B. M., Holst, J. J., Madsbad, S., & Torekov, S. S.
- Affiliations
- University of Copenhagen (DK)
- From the Department of Biomedical Sciences (J.R.L., C.J., S.B.K.J., C.R.J., L.M.O., R.M.C., M.B.B., B.M.S., J.J.H., S.S.T.), the Novo Nordisk Foundation Center for Basic Metabolic Research (J.R.L., C.J., S.B.K.J., C.R.J., L.M.O., R.M.C., J.J.H., S.S.T.), the Department of Clinical Medicine (T.B., J.-E.B.J.), University of Copenhagen, and the Departments of Endocrinology (M.S.S., K.N.B.-M., J.-E.B.J., S.M.) and Clinical Research (T.B.), Copenhagen University Hospital–Amager and Hvidovre, Copenhagen, and the Steno Diabetes Center Copenhagen, Gentofte (M.B.B.) — all in Denmark.
- Amager Hospital (DK)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-05-06
- Volume
- 384
- Issue
- 18
- Pages
- 1719-1730
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3158123746
- Cited by
- 536
- References
- 35
- Citations by year
- 2026: 140 · 2025: 137 · 2024: 86 · 2023: 78 · 2022: 71 · 2021: 23
- FWCI
- 37.66
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, other-oa)
- Funders
- Helse Fonden
- Det Sundhedsvidenskabelige Fakultet, Københavns Universitet
- Danish Diabetes Academy
- Novo Nordisk Fonden (NNF15CC0018486, NNF16OC0019968)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Obesity, Physical Activity, Diet
- Keywords
- obesity, weight loss maintenance, weight regain, liraglutide, physical activity, hypocaloric diet, body fat percentage, GLP-1 receptor agonists, combination therapy, metabolic health
- MeSH terms
- Liraglutide, Adipose Tissue, Adult, Combined Modality Therapy, Exercise Therapy, Female, Humans, Male, Middle Aged, Obesity, Weight Loss, Anti-Obesity Agents, Caloric Restriction, Body Size
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.